Published in Clin Gastroenterol Hepatol on January 24, 2009
Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med (2014) 2.73
Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med (2011) 2.06
Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology (2012) 1.97
Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol (2011) 1.61
Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest (2011) 1.47
The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol (2015) 1.34
Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol (2015) 1.29
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol (2013) 1.18
Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol (2013) 1.17
Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.15
Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr (2012) 1.10
Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res (2010) 1.06
Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol (2010) 1.06
Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis (2014) 1.05
Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis (2013) 0.97
Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer (2013) 0.95
Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up. World J Gastroenterol (2014) 0.94
Infliximab for Crohn's disease: the first 500 patients followed up through 2009. Dig Dis Sci (2012) 0.92
Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol (2012) 0.91
Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol (2014) 0.90
Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines. Ann Gastroenterol (2012) 0.90
New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne) (2014) 0.89
Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses. Ann Oncol (2013) 0.89
Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient (2013) 0.87
Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol (2011) 0.85
Immunomodulators for all patients with inflammatory bowel disease? Therap Adv Gastroenterol (2010) 0.85
Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag (2015) 0.85
Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol (2010) 0.85
A case of rapid growing colonic NK/T cell lymphoma complicated by Crohn's disease. Chin J Cancer Res (2013) 0.85
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol (2013) 0.85
Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? Nat Rev Rheumatol (2011) 0.84
Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis (2014) 0.83
Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol (2011) 0.82
Comparison of pooled risk estimates for adverse effects from different observational study designs: methodological overview. PLoS One (2013) 0.81
Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review. World J Gastroenterol (2014) 0.81
When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol (2010) 0.80
Failure or success of electronic search strategies to identify adverse effects data. J Med Libr Assoc (2012) 0.80
Hodgkin lymphoma following adalimumab for the treatment of Crohn's disease in an adolescent. Dig Dis Sci (2014) 0.80
Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. Clin Exp Gastroenterol (2009) 0.80
Microbiome associations of therapeutic enteral nutrition. Nutrients (2014) 0.79
Non-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int (2009) 0.78
Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis (2016) 0.78
Biologics in paediatric Crohn's disease. Gastroenterol Res Pract (2011) 0.78
Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease. Ther Adv Chronic Dis (2015) 0.78
Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis (2015) 0.78
Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota. Mayo Clin Proc (2015) 0.78
Intestinal Dilation and Platelet:Albumin Ratio Are Predictors of Surgery in Stricturing Small Bowel Crohn's Disease. Clin Gastroenterol Hepatol (2016) 0.78
Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology (2016) 0.77
Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis. J Immunol (2013) 0.77
Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis (2010) 0.77
Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses. Clin Rheumatol (2015) 0.77
Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther (2016) 0.76
Taking Crohn's disease personally. Rambam Maimonides Med J (2013) 0.76
Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol (2015) 0.75
Peripheral T-cell lymphoma in a patient with Crohn's disease. BMJ Case Rep (2013) 0.75
Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease. Clin Gastroenterol Hepatol (2009) 0.75
The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease. Ther Adv Chronic Dis (2010) 0.75
Primary effusion lymphoma-like lymphoma in a patient with inflammatory bowel disease. World J Gastroenterol (2014) 0.75
Rare gastrointestinal lymphomas: The endoscopic investigation. World J Gastrointest Endosc (2015) 0.75
Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. World J Gastrointest Pathophysiol (2015) 0.75
Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds. Oncotarget (2016) 0.75
How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? World J Gastroenterol (2015) 0.75
The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China. Biomed Res Int (2016) 0.75
TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review. World J Gastroenterol (2014) 0.75
Hepatosplenic lymphoma presenting initially as hemophagocytic syndrome in a 21-year-old man with Crohn's disease: a case report and literature review. Can J Gastroenterol (2011) 0.75
Composite lymphoma in a patient with ulcerative colitis: a case report. Int J Hematol Oncol Stem Cell Res (2014) 0.75
Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. Inflamm Bowel Dis (2013) 0.75
Infliximab does not increase colonic cancer risk associated to murine chronic colitis. World J Gastroenterol (2016) 0.75
Inflammatory Bowel Disease in Primary Immunodeficiencies. Curr Allergy Asthma Rep (2017) 0.75
A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. J Gastroenterol (2016) 0.75
Emerging biologics in inflammatory bowel disease. J Gastroenterol (2016) 0.75
The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther (2017) 0.75
Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease. World J Gastroenterol (2017) 0.75
Computed tomography--an increasing source of radiation exposure. N Engl J Med (2007) 41.06
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol (2007) 6.19
Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer (2001) 4.61
Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology (2001) 4.28
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut (2005) 3.86
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology (2006) 2.91
Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut (2008) 2.69
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 2.62
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis (1999) 2.55
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol (2008) 2.41
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol (2008) 2.15
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology (2005) 2.05
Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut (2004) 1.87
Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol (2000) 1.71
Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology (2007) 1.71
Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Digestion (2004) 1.57
Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol (2004) 1.46
Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut (2005) 1.25
Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal (2008) 1.13
Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum (2006) 1.01
Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther (2007) 0.98
Infliximab in the surgical management of complex fistulating anal Crohn's disease. Colorectal Dis (2005) 0.94
Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis (2001) 0.91
Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis (2004) 0.91
Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther (2004) 0.88
Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur J Gastroenterol Hepatol (2006) 0.85
[Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea]. Korean J Gastroenterol (2005) 0.84
Comparison of time trends in Hodgkin and non-Hodgkin lymphoma incidence (1973-97) in East Asia, Europe and USA, from cancer incidence in five continents Vol. IV-VIII. Jpn J Clin Oncol (2008) 0.84
Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol (2003) 0.84
Retreatment and maintenance therapy with infliximab in fistulizing Crohn's disease. Rev Esp Enferm Dig (2004) 0.83
Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning treatment with infliximab. Ann N Y Acad Sci (2007) 0.81
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA (2008) 10.15
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol (2006) 2.97
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology (2005) 2.05
Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med (2012) 1.92
Press releases by academic medical centers: not so academic? Ann Intern Med (2009) 1.91
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
The risk of developing Crohn's disease after an appendectomy: a meta-analysis. Am J Gastroenterol (2008) 1.74
Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology (2007) 1.71
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology (2007) 1.60
Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis (2006) 1.58
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology (2008) 1.56
Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis (2010) 1.42
Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology (2009) 1.29
Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol (2004) 1.25
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis (2011) 1.22
Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists. J Pediatr Gastroenterol Nutr (2009) 1.22
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease. Am J Gastroenterol (2006) 1.21
The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol (2010) 1.19
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology (2012) 1.15
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal (2008) 1.13
Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.13
Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm (2010) 1.11
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg (2008) 1.09
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis (2010) 1.07
Perioperative intranasal mupirocin for the prevention of surgical-site infections: systematic review of the literature and meta-analysis. Infect Control Hosp Epidemiol (2005) 1.06
Risk factors for colorectal cancer in Crohn's colitis: a case-control study. Inflamm Bowel Dis (2006) 1.05
Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials? Inflamm Bowel Dis (2012) 1.00
Acute appendicitis following colonoscopy. J Clin Gastroenterol (2005) 1.00
Risk factors for colon ischemia. Am J Gastroenterol (2004) 1.00
A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2006) 0.99
State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis (2005) 0.98
Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut (2011) 0.97
A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol (2013) 0.96
The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut (2007) 0.96
The effect of computers for weight loss: a systematic review and meta-analysis of randomized trials. J Gen Intern Med (2011) 0.94
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis (2010) 0.93
Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Am J Gastroenterol (2003) 0.92
Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol (2007) 0.92
Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother (2003) 0.92
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis (2011) 0.89
Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. J Crohns Colitis (2013) 0.86
Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol (2011) 0.85
Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol (2008) 0.85
Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire. Inflamm Bowel Dis (2009) 0.85
Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors. Scand J Gastroenterol (2015) 0.84
Efficacy of methotrexate in ulcerative colitis: failure or promise. Inflamm Bowel Dis (2010) 0.83
Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis (2014) 0.83
Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab (2003) 0.82
Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease? Surgery (2011) 0.81
Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. J Hosp Med (2014) 0.81
Serum Proteome Profiles in Stricturing Crohn's Disease: A Pilot Study. Inflamm Bowel Dis (2015) 0.80
Menstrual cycle changes in women with inflammatory bowel disease: a study from the ocean state Crohn's and colitis area registry. Inflamm Bowel Dis (2014) 0.80
Group writing of letters to the editor as the goal of journal club. JAMA (2006) 0.80
Genetics, Genetic Testing, and Biomarkers of Digestive Diseases. Gastroenterology (2015) 0.80
Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2013) 0.80
Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis (2010) 0.78
Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial. JMIR Res Protoc (2015) 0.78
Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting. Inflamm Bowel Dis (2015) 0.78
Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study. Inflamm Bowel Dis (2017) 0.78
Surgery Versus Interferon Alpha-2b Treatment Strategies for Ocular Surface Squamous Neoplasia: A Literature-Based Decision Analysis. Cornea (2016) 0.77
Body image dissatisfaction in patients with inflammatory bowel disease. Inflamm Bowel Dis (2015) 0.77
Evaluation of possible inflammatory bowel disease: a survey of Rhode Island physicians. Med Health R I (2012) 0.77
Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis (2014) 0.77
Babesiosis in a patient on infliximab for Crohn's disease. Inflamm Bowel Dis (2010) 0.77
Within you, without you: is gastroenterology ready to embrace the "exposome"? Gastroenterology (2012) 0.76
Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers. Inflamm Bowel Dis (2016) 0.75
Achieving Synergy: Linking an Internet-Based Inflammatory Bowel Disease Cohort to a Community-Based Inception Cohort and Multicentered Cohort in Inflammatory Bowel Disease. J Med Internet Res (2016) 0.75
Incidence of Crohn's Disease and Ulcerative Colitis in Rhode Island: Report from the Ocean State Crohn's and Colitis Area Registry. Inflamm Bowel Dis (2016) 0.75
Neruocognitive Effects of Metopic Synostosis Based on Severity of Deformity. Plast Reconstr Surg (2015) 0.75
Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study. Inflamm Bowel Dis (2017) 0.75